Chemo after chemoradiation for HPV-positive cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 3 study tests whether giving additional (adjuvant) chemotherapy after standard chemoradiation can help people whose blood test still shows cancer-related HPV DNA. It may help by lowering the risk of the cervical cancer coming back in people who have a positive blood biomarker after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cervical cancer staged FIGO 2018 stage IB3 to IVA
- You already finished the standard treatment that includes chemoradiation with cisplatin
- Your blood test for “cfHPV-DNA” is positive after chemoradiation (for specific HPV types)
- You can do more treatment and have good health basics: life expectancy of at least 12 weeks and activity level score 70+
- Your organs and blood counts meet thresholds (enough white blood cells and platelets, and acceptable kidney and liver blood tests)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether adding chemotherapy after standard chemoradiation helps people with locally advanced cervical cancer. You may be eligible if your MRI after treatment still shows leftover tumor areas and your health and blood tests are within required limits.
This Phase 3 trial tests whether adding chemotherapy after surgery helps people with locally advanced cervical cancer, especially when prior treatment didn’t fully match standard guidelines. It looks at whether this “adjuvant” chemotherapy improves outcomes after neoadjuvant chemotherapy and an extensive hysterectomy.
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
This study looks at whether a PET scan (FDG-PET/CT) and blood HPV testing can help track cervical cancer responses during and after standard chemo-radiation. It may help doctors better understand who is responding and who may need different care.
This trial tests if giving chemotherapy plus an immunotherapy drug before surgery can help shrink tumors and improve outcomes for patients with stage IB2 cervical cancer that has not been treated yet. It might be an option if you have a specific type of cervical cancer that shows a certain protein (PD-L1) on your tumor cells.
This trial tests a combination of chemotherapy (nab-paclitaxel plus cisplatin) given together with radiation therapy for people with locally advanced cervical cancer. The goal is to see if this treatment is safe and effective.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.